The importance of critical evaluation of the literature regarding safety of antidepressant use in pregnancy

Acta Psychiatrica Scandinavica

Volumn 127, Issue 2, 2013, Pages 115-116

  Einarson, A ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

BEHAVIOR DISORDER; CLINICAL EVALUATION; CONGENITAL MALFORMATION; DEPRESSION; DRUG SAFETY; DRUG SCREENING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MATERNAL DISEASE; MEDICAL LITERATURE; NOTE; PERINATAL DRUG EXPOSURE; PREGNANCY OUTCOME; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84872184759     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12046     Document Type: Note

References (5)

1. Byatt N, Deligiannidis K, Freeman M. Antidepressant Use in Pregnancy: A Critical Review Focused on Risks and Controversies. Acta Psychiatr Scand 2013;127:94-114.
2. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14:823-7.
3. Scialli AR, Bérard A. Paroxetine exposure during pregnancy and cardiac malformations. Birth Defects Res A Clin Mol Teratol 2010;88:171-4.
4. www.lawyersandsettlements.com/case/paxil-heart-defects-newborn.html. [Accessed July 20, 2012].
5. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. J Psychiatry Neurosci 2001;26:44-8.